First patient enrolled in Oramed's mid-stage trial of oral insulin capsule

• Oramed (NASDAQ:ORMP) announces that the first patient has been screened in its Phase 2b study of ORMD-0801, its oral insulin capsule, in type 2 diabetics. The randomized, 180-subject, double-blind trial will generate safety and efficacy data that will be the basis for advancing to Phase 3 development.